Cash Injection Fuels Viela Bio's NMOSD FDA Filing

 
• By Jo Shorthouse

New and existing investors in Viela Bio have raised $75m in the latest funding round, allowing the AstraZeneca spin off to progress its NMOSD antibody to regulatory filing in the US. However, established companies may have stolen a march on commercializing a treatment.

Rocket
Do we have lift off? New cash has the potential to propel inebilizumab into orbit • Source: Shutterstock

More from Business

More from Scrip